| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT06499896 Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous… |
critical overall status: Recruiting → Withdrawn |
| 2026-08-15 | NCT06499896 Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous… |
critical Trial withdrawn: slow accrual |
| 2026-08-15 | NCT06499896 Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous… |
Enrollment reduced: 30 -> 0 participants |
| 2026-07-19 | NCT04808999 Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell… |
Primary endpoint(s) modified |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06070012 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Uveal Melanoma | Recruiting |
| NCT05669846 | Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1… | Non Small Cell Lung Cancer | Recruiting |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | Renal Cell Carcinoma | Recruiting |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor… | Melanoma Stage III | Active, Not Recruiting |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1… | Melanoma | Active, Not Recruiting |
| NCT04808999 | Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell… | Squamous Cell Carcinoma | Active, Not Recruiting |